Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue
to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or
mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the
regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.